Liver Cancer Clinical Trial
Official title:
A Multi-centre Open-label Randomised Phase III Trial of the Efficacy of Sodium Thiosulphate in Reducing Ototoxicity in Patients Receiving Cisplatin Chemotherapy for Standard Risk Hepatoblastoma
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Chemoprotective drugs, such as sodium thiosulfate, may protect normal cells from the side
effects of chemotherapy. It is not yet known whether giving sodium thiosulfate is effective
in reducing hearing damage caused by cisplatin in treating young patients with liver cancer.
PURPOSE: This randomized phase III trial is studying how well sodium thiosulfate works to
decrease hearing loss caused by cisplatin in treating young patients with stage I, stage II,
or stage III childhood liver cancer.
OBJECTIVES:
Primary
- To assess the efficacy of sodium thiosulfate (STS) to reduce the hearing impairment
caused by cisplatin chemotherapy.
Secondary
- To carefully monitor any potential impact of STS on response to cisplatin and survival.
- To assess the short- and long-term tolerability of the combination of STS and cisplatin
- To prospectively evaluate and validate biological, radiological and pathological
features of standard-risk hepatoblastoma for future risk adapted management
- To investigate the effect of STS on the formation of cisplatin-DNA adducts.
- To prospectively collect patient DNA specifically for the analysis of possible genetic
factors that may contribute to the development of treatment-related ototoxicity and
nephrotoxicity
OUTLINE: This is a multicenter study. Patients are stratified according to country, median
age (< 15 months vs ≥ 15 months), and PRETEXT tumor classification (I vs II vs III). Patients
are randomized to 1 of 2 treatment arms.
- Arm I (Neoadjuvant and adjuvant cisplatin): Patients receive cisplatin IV over 6 hours
on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive
disease after course 4 are taken off study. Patients without evidence of disease
progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive
cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 2 courses in the
absence of disease progression or unacceptable toxicity.
- Arm II (Neoadjuvant and adjuvant cisplatin and sodium thiosulphate): Patients receive
cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (beginning 6 hours
after completion of cisplatin) on day 1. Treatment repeats every 2 weeks for 4 courses.
Patients with progressive disease after course 4 are taken off study. Patients without
evidence of disease progression proceed to surgery. Beginning within 3 weeks after
surgery, patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15
minutes (as in neoadjuvant therapy) on day 1. Treatment repeats every 2 weeks for 2
courses in the absence of disease progression or unacceptable toxicity.
Patients undergo blood collection and tumor biopsies periodically for biological and
pharmacological studies consisting of biomarker analysis, gene expression profiling, IHC,
proteomic analysis, and gene rearrangement analysis. Patients undergo auditory evaluations at
baseline, and at the completion of study treatment or at an age of at least 3.5 years to
measure ototoxicity and hearing impairment.
After completion of study treatment, patients are followed periodically for at least 5 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03213314 -
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
|
N/A | |
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Recruiting |
NCT05160740 -
Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer
|
N/A | |
Completed |
NCT01906021 -
Study of New Software Used During Ablations
|
N/A | |
Terminated |
NCT04589884 -
Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
|
||
Recruiting |
NCT05953337 -
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
|
N/A | |
Enrolling by invitation |
NCT04466124 -
Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy
|
||
Not yet recruiting |
NCT04053231 -
Hepatocarcinoma Recurrence on the Liver Study - Part2
|
||
Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT03059238 -
Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure
|
Phase 3 | |
Recruiting |
NCT02632188 -
Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT01388101 -
Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor)
|
N/A | |
Completed |
NCT01042041 -
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
|
Phase 1 | |
Terminated |
NCT00903396 -
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
|
Phase 2 | |
Completed |
NCT00980239 -
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver
|
Phase 1 | |
Completed |
NCT00790569 -
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
|
N/A | |
Terminated |
NCT00896467 -
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
|
N/A | |
Completed |
NCT00543777 -
Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease
|
Phase 1/Phase 2 |